PharmTech Drug Digest 11.20
News|Articles|January 10, 2017

Astellas Terminates Agreement with UMN Pharma for Influenza Program

The company announced that it has terminated an agreement made with UMN Pharma for the co-development of influenza vaccine programs in Japan.

On Jan. 10, 2017, Astellas Pharma announced that it has terminated an agreement made on Sept. 21, 2010 between Astellas and UMN Pharma for the co-development and Astellas’ exclusive commercialization of ASP7374 and ASP7373, the cell-culture-based influenza vaccine programs in Japan. Upon the effective date of termination, Astellas will return to UMN Pharma all rights granted under the agreement.

Astellas will withdraw the application for marketing approval of ASP7374 and discontinue the development of ASP7373, the company said in a statement. The company said it will recognize the impairment losses for other tangible assets of four billion yen (approximately US$8,636,330) in the first nine months after the fiscal year ending March 31, 2017. The company is still reviewing the other impact on its financial results.

Source: Astellas

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.